About The GM&C Life Sciences Fund
The GM&C Life Sciences Fund is a venture capital firm founded in 2015. It is primarily based out of Alderley Edge, United Kingdom. As of May 2026, The GM&C Life Sciences Fund has invested in 34 companies. It primarily invests in Seed round in United Kingdom based startups. Its investments are spread across a wide range of sectors from HealthTech to Life Sciences and Enterprise Applications. Most recently it participated in the $***** Series A round of Infex Therapeutics Overall, The GM&C Life Sciences Fund portfolio has seen 1 acquisition, namely Trio Healthcare. A lot of funds co-invest with The GM&C Life Sciences Fund, with names like Catapult Ventures sharing a substantial percentage of its portfolio. The GM&C Life Sciences Fund has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 1 more
Portfolio Acquisitions
Deals in last 12 months
The GM&C Life Sciences Fund's List of Top Investments
The GM&C Life Sciences Fund has a portfolio of 34 companies. Their most notable investments are in Rinicare and BioHabit.Their portfolio spans across United Kingdom and Ireland. They have invested in HealthTech, Life Sciences, Enterprise Applications and 6 other sectors, across stages such as Seed, Series A and 1 more. Here is the list of top investments by The GM&C Life Sciences Fund:
Pencil Biosciences is a provider of gene-editing technology. It is developing an innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases.
Key facts about Pencil Biosciences
- Founded Year: 2018
- Location: Alderley Edge (United Kingdom)
- Valuation: $*****
- Stage: Seed
- Total Funding till date: $10.4M
- Employee Count: 17 as on Jul 31, 2026
- Investors: Octopus Ventures, Martlet Capital and 16 Others
- Latest Funding Round: Seed, Aug 16, 2023, $*****
- Highlight: Editors' Pick
Manufacturer of electrotherapy devices for treating brain tumors. The company's flagship product is GRACE, an implanted device that delivers electric field therapy directly to the tumour resection margins where GBM recurrence takes place.
Key facts about QV Bioelectronics
- Founded Year: 2019
- Location: Manchester (United Kingdom)
- Stage: Series A
- Total Funding till date: $9.63M
- Employee Count: 18 as on Jul 31, 2026
- Investors: SOSV, Ukri and 18 Others
- Latest Funding Round: Series A, Jan 21, 2026, $*****
Blueberry Therapeutics is a modern drug discovery and development company specializing in polymer-drug delivery. Its nanopolymer drug delivery system self-assembles with both small and large molecules (e.g. proteins, peptides, and nucleic acids) and “packages” them into nanoparticles. These nanoparticles enhance cellular delivery into both mammalian and bacterial cells. It is developing OTC products to treat Onychomycosis (fungal nail infection), tinea pedis (athlete’s foot), acne, and acute wounds. Also developing prescription peptide therapeutics to treat Atopic Dermatitis, Inflammatory Bowel Disease.
Key facts about Blueberry Therapeutics
- Founded Year: 2011
- Location: Alderley Edge (United Kingdom)
- Annual Revenue: £0 - £1M as on May 31, 2019
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $23.8M
- Employee Count: 3 as on Jul 31, 2026
- Investors: Medical Incubator Japan, Maven Capital Partners and 49 Others
- Latest Funding Round: Conventional Debt, Jun 08, 2021, $*****
- Highlight: Editors' Pick
Developer of drugs for treating multiple infectious diseases. The company's proprietary platform has developed RESP-X for treating respiratory infections in patients with lungs damaged, MET-X helps to treat urinary tract infections caused by critical priority pathogens, GON-X for gonorrhea, VAP-X helps in the prevention & treatment of hospital-lung infections, and many more.
Key facts about Infex Therapeutics
- Founded Year: 2016
- Location: Alderley Edge (United Kingdom)
- Stage: Series A
- Total Funding till date: $11.8M
- Employee Count: 24 as on Jul 31, 2026
- Investors: Perscitus, LifeArc and 14 Others
- Latest Funding Round: Series A, May 12, 2026, $*****
5. Biorelate
Developer of an artificial intelligence platform for biomedical literature curation and knowledge graph construction. This technology identifies and extracts cause-and-effect relationships from scientific literature to support drug discovery and biological research. The platform enables the analysis of connections between genes, diseases, and chemical entities to assist in target identification, biomarker selection, and indication expansion. By automating the processing of biomedical data, the system provides evidence-based insights for researchers and scientists.
Key facts about Biorelate
- Founded Year: 2014
- Location: Manchester (United Kingdom)
- Stage: Series A
- Total Funding till date: $8.74M
- Employee Count: 35 as on Jul 31, 2026
- Investors: Innovate UK, YFM Equity Partners and 11 Others
- Latest Funding Round: Series A, Nov 29, 2022, $*****
- Highlight: Editors' Pick
The GM&C Life Sciences Fund's Year-on-Year Investment Trends
The GM&C Life Sciences Fund has invested in 34 companies over the last 10 years, with an average of 2 new investments annually in the last 10 years. As of May 2026, it has made 1 investment in this year. Its most recent first time investment was in EarSwitch and most recent follow-on round was in Infex Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 0 | 0 | 0 |
2024 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
2022 | 0 | 0 | 0 |
2021 | 1 | 0 | 1 |
2020 | 2 | 0 | 2 |
2019 | 2 | 0 | 2 |
2018 | 8 | 0 | 8 |
2017 | 3 | 0 | 3 |
The GM&C Life Sciences Fund's Investments by Stage
The GM&C Life Sciences Fund has made 17 investments in Seed stage with an average round size of $1.2M, 4 investments in Series A stage with an average round size of $2.81M and 1 investment in Series B stage with an average round size of $3.3M.Stage of entry | No. of Investments |
|---|---|
Seed | 17 |
Series A | 4 |
Series B | 1 |
Note: We have considered here, only first round of investments
The GM&C Life Sciences Fund's Investments by Sector
The GM&C Life Sciences Fund has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, High Tech and Healthcare. Notably, it has invested in 28 Tech companies, 26 Enterprise (B2B) companies, 11 Software companies and at least 7 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 13 |
HealthTech | 9 |
Enterprise Applications | 4 |
High Tech | 4 |
Healthcare | 3 |
Others | 8 |
Note: We have considered here, only first round of investments
The GM&C Life Sciences Fund's Investments by Geography
The GM&C Life Sciences Fund has made most investments in United Kingdom (21), followed by Ireland where it has made 1 investment.Country | No. of Investments |
|---|---|
United Kingdom | 21 |
Ireland | 1 |
Note: We have considered here, only first round of investments
The GM&C Life Sciences Fund's recent investments
The GM&C Life Sciences Fund has made 1 investments in 2026 so far - Infex Therapeutics.Here are the most recent investments by The GM&C Life Sciences Fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 12, 2026 | United Kingdom | Series A | 9987 | ||
Feb 19, 2024 | United Kingdom | Seed | 4036 | - | |
Aug 16, 2023 | United Kingdom | Seed | 3958 | [+6] | |
Mar 25, 2021 | United Kingdom | Seed | 6771 | [+2] | |
Dec 03, 2020 | United Kingdom | Seed | 8212 | - |
Acquired companies in The GM&C Life Sciences Fund's Portfolio
1 company from The GM&C Life Sciences Fund's portfolio has been acquired. The most recent acquisition was Trio Healthcare in Dec 2024 by Duke Street for $*****.Here are The GM&C Life Sciences Fund's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 02, 2024 | - | - | 3154 |
Team profile of The GM&C Life Sciences Fund
The GM&C Life Sciences Fund has a team of 1 member located in United Kingdom. The GM&C Life Sciences Fund's team does not sit on the board of any company as of now.Co-investors of The GM&C Life Sciences Fund
Over the past 10 years, 64 investors have co-invested in The GM&C Life Sciences Fund's portfolio companies. This includes funds and angels.
- Invested before The GM&C Life Sciences Fund: Northwest Fund, Europa and 21 others have invested in rounds before The GM&C Life Sciences Fund. There are 4 companies where Northwest Fund has invested before The GM&C Life Sciences Fund and 3 companies where Europa has invested before The GM&C Life Sciences Fund.
- Top Co-investors of The GM&C Life Sciences Fund: 17 investors entered a company along with The GM&C Life Sciences Fund. These include investors like Catapult Ventures (5 companies).
- Invested after The GM&C Life Sciences Fund: A total of 24 investors have invested in The GM&C Life Sciences Fund's portfolio after their investments. Top Investors include Maven Capital Partners (2 companies), Northern Powerhouse Investment Fund (2 companies) and o2h ventures (1 company).
Recent News related to The GM&C Life Sciences Fund
•
•
NICE-approved digital mental health platform secures £1.8millionProlific North•Jan 30, 2025•Careloop, Praetura Ventures, The Verge, SFC Capital and 7 others
•
Organ transplant tech pioneer lands £1.4m new fundingProlific North•Sep 03, 2024•ScubaTx, Praetura Ventures, The GM&C Life Sciences Fund
•
GC Angels rounds off £315,000 investment round for innovative medical device companyBusiness Money•Aug 23, 2021•Viscgo, GC Angels, The GM&C Life Sciences Fund, Catapult Ventures and 2 others
•
•
Six-figure investment for medical device firmInsider Media•Apr 29, 2021•Viscgo, Deepbridge Capital, The GM&C Life Sciences Fund
•
Funding agreed for niche digital patient consent technologyTheBusinessDesk.com•Nov 23, 2020•Flynotes, Maven Capital Partners, Catapult, The GM&C Life Sciences Fund
•
Mental health startup secures investment to build appProlific North•Jul 28, 2020•The GM&C Life Sciences Fund
•
Agricultural Biotech Firm Backed By Catapult VenturesInsider Media•Jul 17, 2020•Catapult Ventures, Alderley Park, The GM&C Life Sciences Fund
•
Seed funding investment for Cheshire agricultural biotech ventureTheBusinessDesk.com•Jul 16, 2020•The GM&C Life Sciences Fund, CroBio
